The scene has become a familiar one at COVID-19 testing centers: health care workers clad in head-to-toe personal protective equipment with eyes peeking out behind an N95 mask and goggles. Expressions and smiles are hidden behind a protective layer.
The image becomes even more stark when thinking of those alone, in isolation.
In a study published in the New England Journal of Medicine, scientists led by a team at Columbia University found that people infected with COVID-19 taking hydroxychloroquine do not fare better than those not receiving the drug.
The Trump administration will not implement the Centers for Disease Control and Prevention's 17-page draft recommendation for reopening America, a senior CDC official confirmed to CNN Thursday.
As hospitals were overrun by coronavirus patients in other parts of the world, the Army Corps of Engineers mobilized in the U.S., hiring private contractors to build emergency field hospitals around the country.
The endeavor cost more than $660 million, according to an NPR analysis of federal spending records.
But nearly four months into the pandemic, most of these facilities haven't treated a single patient.
University of Lethbridge researcher Igor Kovalchuk is leading a study on medical cannabis as a potential therapy for COVID-19.
He say Cannabis extracts are showing potential in making people more resistant to the novel coronavirus.
:format(webp)/cdn.vox-cdn.com/uploads/chorus_image/image/66760548/457954872.jpg.0.jpg "Andrew Cuomo and Eric Schmidt walking through a school.")
Gov. Andrew Cuomo is leaning on tech billionaires to rebuild New York after the coronavirus — a reminder of how the mega-rich are consolidating their power and expanding their influence even as they offer to help respond to the pandemic.
Cuomo has tapped Bill Gates’s foundation and former Google CEO Eric Schmidt to “reimagine” New York’s economy, health care system, and school system, the governor said in back-to-back briefings on Tuesday and Wednesday.
The first U.S. patients have been dosed in a clinical trial testing whether four experimental messenger RNA (mRNA) vaccine candidates can prevent infection with the virus that causes 2019 coronavirus disease (COVID-19).
The trials are being conducted at the NYU Grossman School of Medicine and the University of Maryland School of Medicine, the drugmaker said Tuesday.
Scientists at the Los Alamos National Laboratory published a study on Thursday that indicates the now-prevalent strain of coronavirus is a more contagious version of the pathogen first reported in Wuhan, China.
Scientists have created a monoclonal antibody that can defeat the new coronavirus in the lab, an early but promising step in efforts to find treatments and curb the pandemic's spread. From a report:
"The race for a vaccine to combat the new coronavirus is moving faster than researchers and drugmakers expected," reported Dow Jones News Services this week, "with Pfizer Inc. joining several other groups saying that they had accelerated the timetable for testing and that a vaccine could be ready for emergency use in the fall."
